RISK OF CARDIAC TOXICITY FROM ANTHRACYCLINES AND TRASTUZUMAB PATIENTS AGED 50 YEARS OR MORE WITH BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

Background: Elderly patients are at increased risk of development of cardiovascular diseases and some studies have shown that they are also at higher risk of cardiac toxicity from anthracyclines and trastuzumab. In this context, we performed a systematic review and meta-analysis to assess the availa...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-10, Vol.39 (10), p.5845
Main Authors: Farooq, Muhammad Zain, Farooq, Muhammad Saad, Mukthinuthalapat, V Pavan Kedar, Ba Aqee, Sheeba Habeeb, Lingamaneni, Prasanth, Asmi, Nisar, ur Rehman, Muhammad Ebad
Format: Article
Language:English
Subjects:
Age
Anthracycline
Bias
Breast cancer
Cardiovascular diseases
Clinical trials
Confidence intervals
Geriatrics
Health risks
Heart
Heterogeneity
Immunotherapy
Meta-analysis
Monoclonal antibodies
Older people
Regression analysis
Regression coefficients
Risk analysis
Risk assessment
Statistical analysis
Systematic review
Targeted cancer therapy
Toxicity
Trastuzumab
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Elderly patients are at increased risk of development of cardiovascular diseases and some studies have shown that they are also at higher risk of cardiac toxicity from anthracyclines and trastuzumab. In this context, we performed a systematic review and meta-analysis to assess the available evidence and accurately determine the risk of increased age for development of this toxicity, respectively. Materials and Methods: PubMed, EMBASE and SCOPUS databases were searched from inception until 2/5/19 to identify all articles that studied cardiac toxicity with trastuzumab and anthracyclines in patients with breast cancer. We defined elderly as age greater than 50 years and included observational studies and clinical trials with agebased sub group comparisons. Newcastle Ottawa Scale and Cochrane Collaboration tools were used to assess the bias in these studies. Odds ratios comparing cardiac toxicity rates of elderly patients to those younger than 50 years were calculated for each study and pooled estimate of odds ratios were derived using Dersimonian–Laird random effects model. I2 statistic was used to assess heterogeneity, and publication bias was estimated using Egger's regression coefficient. Results: Out of 708 articles retrieved in the initial search, 13 observational studies and clinical trials (n=26,004; elderly age patients=16,544) were included in our quantitative analysis. There was low risk of bias in the studies included and there was no evidence of publication bias (p-value >0.1). Cardiac toxicity was observed in 881 patients and cumulative odds ratio for cardiac toxicity in older patients was 1.5 (95% confidence interval=1.1-2.1, p
ISSN:0250-7005
1791-7530